Skip to main content
Normal View

Seanad Éireann debate -
Wednesday, 26 Jan 2000

Vol. 162 No. 1

Adjournment Matters. - Drug Treatment Services.

I welcome the Minister to the House. I am seeking information in order to determine the policy of his Department in relation to ultra rapid opiate detoxification in which opiate addicts are detoxified through use of the drug Naltrexone. The effect is that under general anaesthetic the drug has the effect of supplanting the narcotics in the brain and nervous system. This brings the addiction to an end in four to six or seven hours. This results in a lot of misery and withdrawal symptoms which means people may not be able to continue to be detoxified or to kick the habit. The first-long term study conducted in October 1988 by the American Psychiatric Association on 120 patients over a six month period found that 55% remained drug free after the treatment. This compares sharply with the normal course of treatment of physeptone or other substitute, such as cold turkey, used under the present system which has in the region of a 10% to 20% success rate.

This issue concerns a number of community groups in the north side of the city, particularly the Dublin 7 against drugs group which organised a major conference at the end of last year. It invited speakers from Britain, the Department of Health and Children and so on and tried to establish the policy of the Eastern Health Board and other health boards in relation to the use of the drugs and whether the drug Naltrexone would be developed on a pilot basis. A number of countries, including Britain, Spain, Switzerland, the United States and Canada are using the drug.

The drug seems to have considerable benefits for pregnant women in particular. The unborn child would benefit from the treatment because, as I understand it, the mother would, as a whole person, be detoxified under the influence of the drug. It seems to me that one of our clinics, perhaps Cherry Orchard or elsewhere, would be a suitable place for conducting a pilot scheme to see whether the drug would be successful. It could be a test period for Ireland. There have been developments since the last conference took place but I want to determine whether the Government is looking seriously at this option. If so, in what capacity and, if not, why not, given that it is operating on a fairly regular basis in other countries that have stringent health regulations and would not do so without having carried out tests and surveys.

I thank the Senator for raising this issue and giving me the opportunity to clarify the position with regard to Naltrexone.

Government policy in relation to drug misuse is that a wide range of drug treatment options should be provided, including methadone maintenance, detoxification and other programmes aimed at those addicted to drugs, especially people who are addicted to heroin. The overall aim is to restore people to a drug free lifestyle. Although it is recognised that this may not be a realistic goal for some hardened drug users, particularly in the short-term, this remains our primary objective. As the Senator will appreciate, decisions regarding the best treatment option for patients rest with those medical consultants specialising in this area.

Naltrexone is an opioid antagonist. It blocks the actions of opioids such as heroin and precipitates withdrawal symptoms in opioid dependent subjects. Since the euphoric action of the opioid agonists is blocked by Naltrexone, it is given to former addicts as an aid to relapse prevention, that is, when a recovering addict takes heroin while on Naltrexone he or she will no longer experience a buzz. However, there is a great temptation for opioid dependent patients, particularly unstable patients or patients experiencing withdrawal, to increase their normal street dose of heroin in an attempt to overcome this Naltrexone block. Patients need to be warned that an attempt to overcome this block could result in opioid intoxification.

Naltrexone is, therefore, only suitable for use in a small number of highly motivated and reliable patients who are supported by a good home and community environment. Treatment must be initiated in a specialised clinic. I understand that the medical consultants working in this area are currently using Naltrexone on a trial basis in some treatment centres in the Eastern Health Board region. New research has suggested that supervised ingestion of Naltrexone provides for a more effective treatment. Supervised administration by family members is one of the aspects that is being researched by these consultants. I, therefore, assure the Senator that under current policy all treatment options are under consideration and should the value of Naltrexone be established in this area, it, too, will be made available for use.

The Seanad adjourned at 8.30 p.m. until 10.30 a.m. on Thursday, 27 January 2000.

Top
Share